FDA Calls for ZantacĀ® to be Removed from the Market
On Wednesday, April 1, 2020, theĀ U.S. Food and Drug Administration (FDA) requested that manufacturers pull all over-the-counter and prescription ranitidine drugs, more commonly known under the brand name ZantacĀ®, immediately from the market. This news is the latest step in an ongoing investigation by the FDA, which found that levels of a probable carcinogen increase over time in the widely used heartburn medications, putting the health and safety of millions of consumers at risk.
Although we are enduring a moment of utter chaos and tragedy in global history as the COVID-19 health crisis rages on, our team at Phillip S. Georges, PLLC is glad to see the FDA continue to take action to protect individuals from the dangers of ranitidine medications. In these times of uncertainty, itās incredibly important to stay informed and know your options if youāve been affected by this drug. Hereās what you need to know about the latest FDA studies, the risks to public health, and filing a ZantacĀ® lawsuit.
WHY DID THE FDA PULL ZANTACĀ®?
The FDA has been investigating levels of the probable human carcinogen,Ā N-nitrosodimethylamine or NDMA, in ranitidine since the summer of 2019 when an independent lab study found low levels of the contaminant in ranitidine. While low levels of NDMA donāt pose a great risk of cancer to humans, the FDA has now determined that NDMA levels in some ranitidine products increase over time, especially when stored at higher temperatures.
New FDA testing has, in fact, confirmed that NDMA levels increase in ranitidine even under normal storage conditions, but spike significantly in higher temperatures, such as those the product may be exposed to during distribution or in the hands of consumers. Testing also showed that the older a ranitidine product is, the greater the level of NDMA.
āThe FDA is committed to ensuring that the medicines Americans take are safe and effective. We make every effort to investigate potential health risks and provide our recommendations to the public based on the best available science. We didnāt observe unacceptable levels of NDMA in many of the samples that we tested. However, since we donāt know how or for how long the product might have been stored, we decided that it should not be available to consumers and patients unless its quality can be assured,ā saidĀ Janet Woodcock, M.D., director of the FDAās Center for Drug Evaluation and Research.
HAS ZANTACĀ® BEEN RECALLED?
In September of 2019, CVS Pharmacy, Walmart, and Walgreens all announced that they would no longer sell over-the-counter ranitidine products, including ZantacĀ®, due to the NDMA concerns. Shortly after,Ā Sanofi voluntarily recalled ZantacĀ® OTC in the United States and Canada. At the time, the FDA warned the public of the potential health risks, but said it did not have enough scientific evidence to recommend halting the use of ranitidine medications. Now, in light of the agencyās latest findings, the FDA has said that letters are being sent to all manufacturers of ranitidine requesting that all products be withdrawn from the market.
WHAT SHOULD I DO IF IāM TAKING ZANTACĀ®?
Many users of this household drug thatāsĀ prescribed more than 15 million times a yearĀ are understandably worried about what they should do now. If you or a loved one are currently taking any ranitidine tablets or liquid medications, the FDA has advised that you stop, dispose of them properly, and not buy more.
If youād like to continue treating heartburn or acid reflux, it is recommended that you consider other over-the-counter options that do not carry the same risk or speak with your healthcare professional about other treatment options if youāre taking prescription ranitidine.
I TOOK ZANTACĀ® AND NOW HAVE CANCER. CAN I FILE A ZANTACĀ® LAWSUIT?
If you took ZantacĀ® (ranitidine) and have since been diagnosed with cancer, youāre not alone and you may be able to take legal action. ZantacĀ® lawsuits are currently being filed across the nation, alleging that overexposure to levels of NDMA present in the heartburn drug caused users to develop cancer. Whatās more, these lawsuits claim that ranitidine manufacturers, such as Sanofi, knew about the potential risk of cancer associated with the drugs but failed to warn the public.
Sadly, this happens all too often. When big drug manufacturers choose to put profits before people, it can devastate lives, taking mothers, fathers, family members, and friends away from their loved ones. If you have lost a loved one or are suffering with a cancer diagnosis yourself after taking ZantacĀ®, you may be entitled to money for the financial and emotional losses youāve endured.
DONāT LEAVE YOUR RIGHTS UP TO CHANCE. CALL WOLF OF JUSTICEā¢!
The deep-pocketed manufacturers of ZantacĀ® undoubtedly have large legal teams on their side. If you believe you or a loved one has been injured by a ranitidine drug, donāt leave your legal rights up to chance. Put Wolf of Justice⢠at Phillip S. Georges, PLLC on YOUR side and even the playing field. Weāre a local law firm with a national reputation for holding careless drug companies responsible for their actions.
The latest FDA announcement is a step in the right direction, but our mission is to help individuals who have been harmed by these dangerous drugs get the justice and compensation they deserve. You can contact us today at 1 (800) 287-1500 or fill out our contact form to find out if you qualify for a ZantacĀ® lawsuit. Thereās never a cost to you unless we put money in YOUR pocket.
Share This Story, Choose Your Platform!
PHILLIP S. GEORGES
As an accomplished trial lawyer, Attorney Phil Georges has tried over 100 cases and successfully resolved thousands of others. The honors he has accrued across his illustrious career are vast; he was appointed to the Civil Plaintiff Executive Committee of the National Trial Lawyers. He also received Diplomat status and was named among the Top 100 Civil Trial Lawyers in Wisconsin by the National Trial Lawyers. He brings this experience and history of success to serve injured people across Arizona, Florida, Illinois, Kentucky, Tennessee, Virginia, and Wisconsin.

